Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases.
Endothelial cells play a pathological role in cancer and chronic inflammation and are therefore attractive targets for therapeutic intervention. This review focuses on endothelial cell specific drug targeting strategies for the treatment of these diseases. The cellular and molecular processes involved in the activation of endothelial cells in angiogenesis and inflammation will be reviewed. Various target epitopes expressed by activated endothelium suitable for targeting purposes, design and development of drug-carrier complexes, drugs of interest which might interfere with endothelial cell activation, as well as in vitro and in vivo experimental approaches to study (intra) cellular drug delivery will be discussed.
Schraa
Astrid J
AJ
Department of Pathology and Laboratory Medicine, Medical Biology Section, Tumor Immunology Laboratory, Groningen University Institute for Drug Exploration (GUIDE), Groningen, The Netherlands. a.j.schraa@med.rug.nl
Everts
Maaike
M
Kok
Robbert J
RJ
Asgeirsdóttir
Sigridur A
SA
Meijer
Dirk K F
DK
de Leij
Lou F M H
LF
Molema
Grietje
G
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D004337:Drug Carriers; D016503:Drug Delivery Systems / Q000379:methods*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D004337:Drug Carriers